Recurrent vulvovaginal candidiasis (RVVC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook

Thelansis's "Recurrent Vulvovaginal Candidiasis (RVVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Vulvovaginal Candidiasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Vulvovaginal Candidiasis (RVVC) Overview

Recurrent vulvovaginal candidiasis (RVVC) is a chronic gynecological condition characterized by recurrent episodes of vulvovaginal Candida infection, typically defined as three or more symptomatic episodes within a year. The majority of cases are caused by Candida albicans, although non-albicans species such as Candida glabrata are increasingly recognized and are often associated with antifungal resistance and treatment difficulty. Common symptoms include vulvovaginal itching, burning, irritation, pain, and abnormal discharge, significantly impacting quality of life, emotional well-being, and daily functioning.

RVVC pathogenesis involves complex interactions between fungal virulence, host immune response, hormonal factors, antibiotic exposure, and vaginal microbiome imbalance. While certain risk factors such as diabetes, immunosuppression, and hormonal changes contribute to disease recurrence, many patients present without identifiable underlying causes. Diagnosis relies on clinical evaluation supported by fungal culture or molecular testing to confirm Candida species and detect resistant infections.

Standard management includes topical or oral azole antifungal therapy, particularly long-term fluconazole suppression; however, recurrence following treatment discontinuation and increasing antifungal resistance remain major clinical challenges. Recently approved novel antifungal therapies and emerging immunomodulatory approaches are expanding the treatment landscape and addressing significant unmet needs in long-term disease control.

Key Highlights

• In Germany, the diagnosed RVVC prevalence pool is projected to increase from approximately 622,099 to 715,204 by 2035, reflecting a growing disease burden.
• Increasing prevalence of non-albicans Candida species is contributing to greater antifungal resistance and treatment complexity.
• Persistent recurrence and relapse continue to significantly impact patient quality of life and healthcare utilization.
• Novel antifungal agents are expanding treatment options for patients with recurrent or resistant disease.
• Growing awareness of women's health conditions and improved diagnostic testing are supporting increased patient identification and treatment uptake.

Market Overview

• The France RVVC market is projected to grow from approximately $24 MN to $60 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing adoption of novel antifungal therapies for recurrent disease management
• Rising awareness and diagnosis of resistant and recurrent infections
• Market value growth is driven by long-term suppressive treatment strategies and increasing demand for durable therapeutic options.
• Future market growth will depend on next-generation antifungal agents, resistance-targeted therapies, and preventive therapeutic approaches including vaccines and immunotherapies.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• LimmaTech Biologics AG
• Mycovia Pharmaceuticals Inc.